Beyond Symptom Suppression: The Multitargeted Reversal of Chronic Pain by Maresin1. [PDF]
Drug Des Devel TherWang F, Yang Y, Wang W, Shi Q, Fan B.
europepmc +1 more source
Digital N‐of‐1 trials and their application in experimental physiology
Experimental Physiology, Volume 111, Issue 8, Page 3525-3545, 1 August 2026.Abstract Traditionally, studies in experimental physiology have been conducted in small groups of human participants, animal models or cell lines. Identifying optimal study designs that achieve sufficient power for drawing proper statistical inferences to detect group level effects with small sample sizes has been challenging. Moreover, average effects
Stefan Konigorski +2 more
wiley +1 more source
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands. [PDF]
Int J Technol Assess Health CareVersteeg JW +5 more
europepmc +1 more source
Advances in Cell and Gene Therapy for Rare Disease Treatment. [PDF]
Int J Stem CellsBaek HJ, Nam Y, Rim YA, Ju JH.
europepmc +1 more source
From co-creation to compounding value: A new model of rare disease science communication in China. [PDF]
Intractable Rare Dis ResChen Y.
europepmc +1 more source
GPR37 modulates body weight and insulin sensitivity in a sex-biased manner. [PDF]
PLoS OneAhmed M +6 more
europepmc +1 more source
An integrative neuropharmacological review of Huntington's disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations. [PDF]
Front PharmacolSenousy MA +7 more
europepmc +1 more source
HTA Evidence in Rare Diseases: Just Rare or Also Special? [PDF]
PharmacoeconomicsBasu A +3 more
europepmc +1 more source
How to evaluate rare disease policy effectiveness based on policy modeling consistency (PMC) index model: A quantitative assessment of policy implementation in China. [PDF]
Intractable Rare Dis ResZhao Y +6 more
europepmc +1 more source